Jay Hsu

1.0k total citations
31 papers, 765 citations indexed

About

Jay Hsu is a scholar working on Psychiatry and Mental health, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Jay Hsu has authored 31 papers receiving a total of 765 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Psychiatry and Mental health, 5 papers in Pharmacology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Jay Hsu's work include Schizophrenia research and treatment (19 papers), Bipolar Disorder and Treatment (16 papers) and Attention Deficit Hyperactivity Disorder (11 papers). Jay Hsu is often cited by papers focused on Schizophrenia research and treatment (19 papers), Bipolar Disorder and Treatment (16 papers) and Attention Deficit Hyperactivity Disorder (11 papers). Jay Hsu collaborates with scholars based in United States, Germany and Canada. Jay Hsu's co-authors include Antony Loebel, Josephine Cucchiaro, Robert Silva, Kaushik Sarma, Gary Sachs, Hans Kröger, Jane Xu, Debra Phillips, Henry A. Nasrallah and Leslie Citrome and has published in prestigious journals such as American Journal of Psychiatry, Annals of the New York Academy of Sciences and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Jay Hsu

31 papers receiving 745 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jay Hsu United States 11 664 183 98 75 52 31 765
Kaushik Sarma United States 9 751 1.1× 220 1.2× 84 0.9× 87 1.2× 22 0.4× 16 854
Anna Sparshatt United Kingdom 13 405 0.6× 150 0.8× 77 0.8× 71 0.9× 22 0.4× 16 581
Joseph Stringfellow United States 7 482 0.7× 130 0.7× 90 0.9× 31 0.4× 27 0.5× 19 669
Quynh-Van Tran United States 16 448 0.7× 311 1.7× 63 0.6× 96 1.3× 14 0.3× 20 689
Luke Vano United Kingdom 5 545 0.8× 89 0.5× 96 1.0× 122 1.6× 34 0.7× 10 823
Maosheng Fang China 15 523 0.8× 141 0.8× 146 1.5× 104 1.4× 37 0.7× 29 974
Dana D. Nguyen United States 11 523 0.8× 113 0.6× 92 0.9× 55 0.7× 39 0.8× 16 842
Eva Kohegyi United States 10 444 0.7× 158 0.9× 161 1.6× 47 0.6× 12 0.2× 14 772
Bruce L. Saltz United States 13 912 1.4× 109 0.6× 132 1.3× 48 0.6× 27 0.5× 15 1.2k

Countries citing papers authored by Jay Hsu

Since Specialization
Citations

This map shows the geographic impact of Jay Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Hsu more than expected).

Fields of papers citing papers by Jay Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Hsu. The network helps show where Jay Hsu may publish in the future.

Co-authorship network of co-authors of Jay Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Hsu. A scholar is included among the top collaborators of Jay Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Hsu. Jay Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
5.
6.
Findling, Robert L., Lenard A. Adler, Thomas Spencer, et al.. (2019). Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial. Journal of Child and Adolescent Psychopharmacology. 29(2). 80–89. 29 indexed citations
7.
Wigal, Sharon B., Seth C. Hopkins, Kenneth S. Koblan, et al.. (2019). Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study. Journal of Attention Disorders. 24(2). 192–204. 19 indexed citations
8.
Goldman, Robert, Ann Childress, Sharon B. Wigal, et al.. (2018). 180 Efficacy of Dasotraline in Children With Attention Deficit Hyperactivity Disorder in a Laboratory Classroom Setting. CNS Spectrums. 23(1). 103–103. 1 indexed citations
9.
Allen, Michael H., et al.. (2017). Efficacy of lurasidone in the treatment of agitation: A post hoc analysis of five short-term studies in acutely ill patients with schizophrenia. General Hospital Psychiatry. 47. 75–82. 11 indexed citations
10.
11.
Correll, Christoph U., et al.. (2016). Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study. CNS Spectrums. 21(5). 393–402. 30 indexed citations
12.
Chapel, Sunny, et al.. (2015). Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis. Clinical Therapeutics. 38(1). 4–15. 5 indexed citations
13.
14.
McEvoy, Joseph P., Leslie Citrome, David Hernández, et al.. (2013). Effectiveness of Lurasidone in Patients with Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotics. The Journal of Clinical Psychiatry. 74(2). 170–179. 52 indexed citations
15.
Nasrallah, Henry A., Robert Silva, Debra Phillips, et al.. (2013). Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study. Journal of Psychiatric Research. 47(5). 670–677. 119 indexed citations
16.
Stahl, Stephen M., et al.. (2013). Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo. The Journal of Clinical Psychiatry. 74(5). 507–515. 69 indexed citations
17.
Citrome, Leslie, Peter J. Weiden, Joseph P. McEvoy, et al.. (2013). Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectrums. 19(4). 330–339. 39 indexed citations
18.
Harvey, Philip D., Cynthia Siu, Jay Hsu, et al.. (2013). Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension. European Neuropsychopharmacology. 23(11). 1373–1382. 65 indexed citations
19.
Correll, Christoph U., et al.. (2013). P.3.d.045 Early improvement predicts endpoint response to lurasidone in schizophrenia: pooled analysis of five double-blind trials. European Neuropsychopharmacology. 23. S485–S485. 1 indexed citations
20.
Romac, Joelle, et al.. (2006). Local disruption of the celiac ganglion inhibits substance P release and ameliorates caerulein-induced pancreatitis in rats. American Journal of Physiology-Gastrointestinal and Liver Physiology. 291(1). G128–G134. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kaushik Sarma Breakdown of academic impact, for papers by Anna Sparshatt Breakdown of academic impact, for papers by Joseph Stringfellow Breakdown of academic impact, for papers by Quynh-Van Tran Breakdown of academic impact, for papers by Luke Vano Breakdown of academic impact, for papers by Maosheng Fang Breakdown of academic impact, for papers by Dana D. Nguyen Breakdown of academic impact, for papers by Eva Kohegyi Breakdown of academic impact, for papers by Bruce L. Saltz
Rankless by CCL
2026